UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/593,850	09/22/2006	Philippe Moser	C 2939 PCT/US	4436
23657 FOX ROTHSC	7590 04/01/200 HILD LLP	EXAMINER		
2000 MARKET		WINSTON, RANDALL O		
PHILADELPH	IA, PA 19103		ART UNIT	PAPER NUMBER
			1655	
			MAIL DATE	DELIVERY MODE
			04/01/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Communication		Α	Application N	oplication No. Applicant(s)				
			10/593,850		MOSER ET AL.			
Office Action Summary			Examiner		Art Unit			
		F	Randall Winst	on	1655			
The MAILING Period for Reply	DATE of this commun	ication appea	ars on the co	ver sheet with the c	orrespondence ad	ddress		
WHICHEVER IS LO - Extensions of time may be after SIX (6) MONTHS fro - If NO period for reply is sp - Failure to reply within the same and the sa	ATUTORY PERIOD FOR NGER, FROM THE ME available under the provisions on the mailing date of this communities above, the maximum states of extended period for reply office later than three months at ment. See 37 CFR 1.704(b).	AILING DAT of 37 CFR 1.136(a nunication. atutory period will a will, by statute, ca	E OF THIS (a). In no event, h apply and will exp ause the application	COMMUNICATION bwever, may a reply be tin ire SIX (6) MONTHS from in to become ABANDONE	N. nely filed the mailing date of this of D (35 U.S.C. § 133).	•		
Status								
1) Responsive to	communication(s) file	nd on 22 Sent	tember 2006	:				
· <u> </u>	Responsive to communication(s) filed on <u>22 September 2006</u> . This action is FINAL . 2b)⊠ This action is non-final.							
′ =		<i>′</i> —			secution as to the	e merits is		
<i>'</i> — · · ·	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims	·	,	, ,	,				
· <u> </u>	is/are pending in the a	nnlication						
	Claim(s) <u>1-20</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
	5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected.							
	_ is/are rejected. _ is/are objected to.							
	_ is/are objected to: are subject to restriction	on and/or ele	action require	ment				
0)[2] Claim(s) <u>1-20</u>	are subject to restriction	on and/or ele	ction require	ment.				
Application Papers								
9)☐ The specification	on is objected to by the	e Examiner.						
10)☐ The drawing(s)	filed on is/are:	a)∏ accept	ted or b)⊟ o	objected to by the I	Examiner.			
Applicant may n	ot request that any objec	ction to the dra	awing(s) be he	eld in abeyance. See	e 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority under 35 U.S.C	:. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
	s Patent Drawing Review (P Statement(s) (PTO/SB/08)	PTO-948)	4) [5) [6) [Interview Summary Paper No(s)/Mail Da Notice of Informal F Other:	ate			

Application/Control Number: 10/593,850 Page 2

Art Unit: 1655

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121 and 372:

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

The various distinct therapeutic cosmetic treatments from the Markush Group instantly claimed (as recited in claim 16) - i.e:

A) inhibiting the synthesis of melanin and decreasing the effects of skin pigmentation.

- B) stimulating the growth and metabolism of human fibroblasts.
- C) anti-aging and/or anti-wrinkle effect and providing a revitalizing or rejuvenating effect on stressed or tired skin and promoting the repair of aged and/or photo-aged skin and providing an appearing and anti-irritation effect against oxidative stress and pollutants and providing an antioxidant effect and protecting against UV or IR radiation.
 - D) promoting hair growth or the delay of hair loss.
 - E) providing a protease inhibition effect.

Applicant is required, in reply to this action, to elect a single species (<u>i.e.</u>, <u>elect a therapeutic cosmetic treatment from among Groups A-E above</u>): which the claims shall be restricted if no generic claim is finally held to be allowable.

The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The following claim(s) are generic: claims 1, 10 and 17

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: Each of the recited treatments are distinct because they are different and distinct therapies which do not require, or do not necessarily require, treating the same patient population.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Randall Winston whose telephone number is 571-272-0972. The examiner can normally be reached on 8AM-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on 571-272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/593,850 Page 4

Art Unit: 1655

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

RW

/Christopher R. Tate/ Primary Examiner, Art Unit 1655